ATR-107

• Description :

  ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R) . ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus[1].

• Product Name Alternative :

  PF-05230900

• UNSPSC :

  12352203

• Target :

  Interleukin Related

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Purity :

  98.62

• Molecular Weight :

  (143.42 kDa)

• References & Citations :

  [1]Hua F, et al. Anti-IL21 receptor monoclonal antibody (ATR-107) : Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2014 Jan;54 (1) :14-22.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 1